Abbott Laboratories Stock Swiss Exchange
Equities
ABT
US0028241000
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93 CHF | -.--% | -.--% | -.--% |
Apr. 29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
Apr. 26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
Sales 2024 * | 41.7B 37.83B | Sales 2025 * | 44.74B 40.58B | Capitalization | 184B 167B |
---|---|---|---|---|---|
Net income 2024 * | 5.96B 5.41B | Net income 2025 * | 7.18B 6.52B | EV / Sales 2024 * | 4.54 x |
Net Debt 2024 * | 5.47B 4.96B | Net cash position 2025 * | 640M 581M | EV / Sales 2025 * | 4.09 x |
P/E ratio 2024 * |
30.9
x | P/E ratio 2025 * |
26.3
x | Employees | 114,000 |
Yield 2024 * |
2.05% | Yield 2025 * |
2.19% | Free-Float | 86.73% |
Latest transcript on Abbott Laboratories
6 months | +2.20% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Ford
CEO | Chief Executive Officer | 50 | 14-12-31 |
Philip Boudreau
DFI | Director of Finance/CFO | 51 | 96-12-31 |
Scott House
CTO | Chief Tech/Sci/R&D Officer | - | 89-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Starks
BRD | Director/Board Member | 69 | 17-02-15 |
John Stratton
BRD | Director/Board Member | 63 | 17-06-28 |
Nancy McKinstry
BRD | Director/Board Member | 65 | 11-12-08 |
Date | Price | Change |
---|---|---|
24-05-06 | 93 | -.--% |
24-05-03 | 93 | -.--% |
24-05-02 | 93 | -.--% |
24-04-30 | 93 | -.--% |
Delayed Quote Swiss Exchange, February 19, 2024 at 11:31 am EST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.75% | 108B | |
-2.97% | 67.82B | |
+4.48% | 51.05B | |
+9.09% | 44.67B | |
+3.63% | 41.78B | |
+3.12% | 26.78B | |
+4.10% | 26.59B | |
+15.32% | 25.86B | |
-0.94% | 25.03B |
- Stock Market
- Equities
- ABT Stock
- ABT Stock